HBK Sorce Advisory LLC Buys 42,951 Shares of Capricor Therapeutics, Inc. $CAPR

HBK Sorce Advisory LLC raised its stake in Capricor Therapeutics, Inc. (NASDAQ:CAPR) by 33.7% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 170,577 shares of the biotechnology company’s stock after purchasing an additional 42,951 shares during the quarter. HBK Sorce Advisory LLC owned approximately 0.37% of Capricor Therapeutics worth $1,141,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in CAPR. Octagon Capital Advisors LP acquired a new stake in shares of Capricor Therapeutics in the 1st quarter valued at approximately $4,270,000. Goldman Sachs Group Inc. raised its position in Capricor Therapeutics by 39.5% during the first quarter. Goldman Sachs Group Inc. now owns 411,141 shares of the biotechnology company’s stock worth $3,902,000 after acquiring an additional 116,373 shares in the last quarter. Woodline Partners LP lifted its stake in Capricor Therapeutics by 15.8% in the first quarter. Woodline Partners LP now owns 729,318 shares of the biotechnology company’s stock valued at $6,921,000 after acquiring an additional 99,384 shares during the last quarter. Nuveen LLC acquired a new stake in Capricor Therapeutics in the first quarter valued at $846,000. Finally, AWM Investment Company Inc. bought a new position in shares of Capricor Therapeutics in the 1st quarter valued at about $833,000. Institutional investors and hedge funds own 21.68% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on the stock. Oppenheimer upped their target price on shares of Capricor Therapeutics from $22.00 to $54.00 and gave the company an “outperform” rating in a report on Monday, December 8th. Piper Sandler reaffirmed an “overweight” rating and issued a $45.00 price objective (up from $20.00) on shares of Capricor Therapeutics in a research report on Wednesday, December 10th. Maxim Group lifted their target price on Capricor Therapeutics from $25.00 to $50.00 and gave the stock a “buy” rating in a research note on Thursday, December 4th. Roth Capital increased their price target on Capricor Therapeutics from $12.00 to $13.00 and gave the company a “buy” rating in a research note on Tuesday, November 11th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Capricor Therapeutics in a report on Monday, December 22nd. Nine investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Capricor Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $40.82.

Capricor Therapeutics Trading Up 1.2%

NASDAQ:CAPR opened at $30.04 on Tuesday. The stock has a 50 day simple moving average of $14.25 and a 200 day simple moving average of $10.04. The stock has a market cap of $1.37 billion, a P/E ratio of -16.69 and a beta of 0.62. Capricor Therapeutics, Inc. has a 1-year low of $4.30 and a 1-year high of $40.37.

Capricor Therapeutics (NASDAQ:CAPR) last posted its quarterly earnings data on Monday, November 10th. The biotechnology company reported ($0.54) earnings per share for the quarter, hitting the consensus estimate of ($0.54). As a group, sell-side analysts forecast that Capricor Therapeutics, Inc. will post -1.21 EPS for the current year.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company’s leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.